Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893491 | 1.00 | KMT2A (0.58) | KMT2AHDAC1ALDH1A1HTTMAPT | |
| SCHEMBL14182616 | 0.87 | KMT2A (0.49) | KMT2AHDAC1ALDH1A1HTTMAPT | |
| SCHEMBL8262991 | 0.85 | KMT2A (0.48) | KMT2AHDAC1ALDH1A1HTTMAPT | |
| SCHEMBL4894599 | 0.83 | HDAC1 (0.56) | KMT2AHDAC1MAPTNPC1HDAC2 | |
| SCHEMBL4897229 | 0.81 | HDAC1 (0.52) | KMT2AHDAC1NPC1POLBMEN1 | |
| SCHEMBL4897402 | 0.81 | HDAC1 (0.59) | KMT2AHDAC1MAPTNPC1POLB | |
| SCHEMBL2404162 | 0.80 | ALDH1A1 (0.53) | KMT2AALDH1A1HTTMAPTMEN1 | |
| SCHEMBL23673663 | 0.79 | NPC1 (0.73) | KMT2AALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL27720607 | 0.76 | KMT2A (0.58) | KMT2AALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL4887589 | 0.76 | HDAC1 (0.47) | KMT2AHDAC1SMN1; SMN2NPC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | KMT2A 57/4885HDAC1 1/4885ALDH1A1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.